Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label NurOwn in prodromal to mild Alzheimer's disease
NL-OMON50920Phase 2Withdrawn
- Sponsor
- Worldwide Clinical Trials
- Start
- May 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MSC-NTF in Alzheimer's disease (AD), sponsored by Worldwide Clinical Trials. Primary endpoint: Biomarker and safety evaluation. Planned start May 2021; status: withdrawn.
02
Drugs
MSC-NTF
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON50920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50920.